Literature DB >> 17305879

Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion.

C-M Chu1, Y-F Liaw.   

Abstract

In high endemic areas of hepatitis B virus (HBV) infection, the vast majority of infection is acquired perinatally or during early childhood. The age of the patient is, therefore, almost equivalent to the duration of HBV infection. The natural history of chronic HBV infection consists of three chronological phases: immune tolerance, immune clearance and low replicative phases. The prevalence of hepatitis B e antigen (HBeAg) in asymptomatic HBV carriers is around 90% before 15 years of age, and decreases remarkably to less than 10% after 40 years of age. The immune clearance phase is characterized by a series of hepatitis flares and remissions. These will be followed eventually by HBeAg seroconversion, which is usually accompanied by remission of liver disease and confers favourable outcome. However, patients with persistent HBeAg seropositivity over 40 years of age are associated with a significantly higher risk for progression to cirrhosis than those with HBeAg seroconversion before 40 years of age, and thus should be considered as patients with 'delayed' HBeAg seroconversion. Antiviral or immunomodulatory therapy should be considered seriously for these patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17305879     DOI: 10.1111/j.1365-2893.2006.00810.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  44 in total

1.  Characteristics of chronic hepatitis B patients who underwent liver biopsies.

Authors:  W Chotiyaputta; B Degertekin; B J McKenna; N Samala; R J Fontana; A S F Lok
Journal:  J Viral Hepat       Date:  2010-08-17       Impact factor: 3.728

2.  A simulation shows that early treatment of chronic hepatitis B infection can cut deaths and be cost-effective.

Authors:  Sarah E Post; Neetu Khurana Sodhi; Chia-Hui Peng; Kejia Wan; Henry J Pollack
Journal:  Health Aff (Millwood)       Date:  2011-02       Impact factor: 6.301

Review 3.  Hepatitis B virus genotypes and variants.

Authors:  Chih-Lin Lin; Jia-Horng Kao
Journal:  Cold Spring Harb Perspect Med       Date:  2015-05-01       Impact factor: 6.915

4.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

Authors:  Norah A Terrault; Anna S F Lok; Brian J McMahon; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; Robert S Brown; Natalie H Bzowej; John B Wong
Journal:  Hepatology       Date:  2018-04       Impact factor: 17.425

5.  Natural history of chronic hepatitis B virus infection in children in Japan: a comparison of mother-to-child transmission with horizontal transmission.

Authors:  Tomoko Takano; Hitoshi Tajiri; Satoyo Hosono; Ayano Inui; Jun Murakami; Kosuke Ushijima; Yoko Miyoshi; Yuri Etani; Daiki Abukawa; Mitsuyoshi Suzuki; Stephen Brooks
Journal:  J Gastroenterol       Date:  2017-02-09       Impact factor: 7.527

6.  Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation.

Authors:  Cheng-Yuan Peng; Chih-Bin Chen; Hsueh-Chou Lai; Wen-Pang Su; Po-Heng Chuang; Hong-Dar Isaac Wu; Long-Bin Jeng
Journal:  Hepatol Int       Date:  2010-12-16       Impact factor: 6.047

Review 7.  Barriers to screening for hepatitis B virus infection in Asian Americans.

Authors:  Ke-Qin Hu; Calvin Q Pan; Diane Goodwin
Journal:  Dig Dis Sci       Date:  2011-08-23       Impact factor: 3.199

Review 8.  Chronic hepatitis B in children and adolescents: epidemiology and management.

Authors:  Mona Abdel-Hady; Deirdre Kelly
Journal:  Paediatr Drugs       Date:  2013-08       Impact factor: 3.022

9.  Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.

Authors:  Yun-Fan Liaw; Nancy Leung; Jia-Horng Kao; Teerha Piratvisuth; Edward Gane; Kwang-Hyub Han; Richard Guan; George K K Lau; Stephen Locarnini
Journal:  Hepatol Int       Date:  2008-05-10       Impact factor: 6.047

10.  Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa.

Authors:  M E Mendy; T Welzel; O A Lesi; P Hainaut; A J Hall; M H Kuniholm; S McConkey; J J Goedert; S Kaye; S Rowland-Jones; H Whittle; G D Kirk
Journal:  J Viral Hepat       Date:  2009-10-27       Impact factor: 3.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.